Journal of Clinical Oncology, Vol 26, No 21 (July 20), 2008: pp. 3656
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2008.17.6016
In Reply
Harold J. Burstein,
Erica L. Mayer
Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Drs Dang, Norton, and Hudis raise important questions about how much pilot or feasibility data should be required before widespread adoption of a new regimen or variant, especially in an evolving field like adjuvant trastuzumab-based therapy. Relevant considerations include the generalizability of the patient population and the assurances as to efficacy and safety. When appraising exploratory studies, point estimates of risk are probably less clinically significant than confidence intervals, given the small numbers of events and inherent patient selection factors. As we noted, trastuzumab effects may be so potent as to render the choice of specific chemotherapy regimens less material, and cardiac safety may be less of an issue if patients with higher ejection fractions, especially after anthracycline therapy, are treated. Nonetheless, the proven survival advantage and extensive safety experience reported among patients with HER-2–positive breast cancer receiving trastuzumab/chemotherapy in the published phase III trials informs our current preference for those treatment plans.
AUTHORS DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The author(s) indicated no potential conflicts of interest.
Related Correspondence
- Dose-Dense Chemotherapy With Trastuzumab Is an Appropriate Option
Chau Dang, Larry Norton, and Clifford Hudis
JCO 2008 26: 3655-3656
[Full Text]
|